COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
Share  
Tweet  
@CovidAnalysis
Early treatmentEarly
88%
31 IVM studies
11 peer reviewed

Early treatment and prophylactic use show high efficacy
100% of studies report positive effects. 88% is the median improvement.
All studiesAll
80%
100% of studies report positive effects.
 
Search:  
Restrict:    All    Early    Late    PrEP    PEP
11/29
Meta
META
Early, Late, PrEP, PEP
Covid Analysis (Preprint) (meta analysis)
Ivermectin is effective for COVID-19: meta analysis of 21 studies
Ivermectin is effective for COVID-19. 100% of studies report positive effects. The probability that an ineffective treatment generated results as positive as the 21 studies to date is estimated to be 1 in 2 million (p = 0.00000048). Earl..
11/28
Positive
POSITIVE
PrEP
Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231 (Peer Reviewed)
death, ↓99.4%, p=0.08 Ivermectin benefit: from scabies to COVID-19, an example of serendipity
69 residents of a French care home, median age 90, were treated with ivermectin for a scabies outbreak. 7 of 69 treated patients had probable or certain COVID-19, with no serious cases and no deaths. In comparable care homes in the same ..
11/28
Positive
POSITIVE
PrEP
Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248 (Peer Reviewed)
cases, ↓78.0%, p<0.02 A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases.
11/24
Positive
POSITIVE
Late
Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1 (Preprint)
death, ↓81.8%, p=0.001 Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
82% lower mortality with ivermectin. RCT with 180 hospitalized patients showing reduced mortality and hospital stay with ivermectin, with a wide margin of safety. All patients received SOC including low dose HC Q.
11/22
Animal
ANIMAL
Animal
de Melo et al., bioRxiv, doi:10.1101/2020.11.21.392639 (Preprint)
Anti-COVID-19 efficacy of ivermectin in the golden hamster
Hamster study finding significantly lower COVID-19 pathology although not finding lower viral load at the dosage used. Ivermectin dramatically reduced the Il-6/Il-10 ratio in lung tissue, which may account for the more favorable clinical ..
11/18
Positive
POSITIVE
Late
Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223 (Preprint)
death, ↓99.1%, p=0.04 Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience
Retrospective 976 hospitalized patients with 34 treated with ivermectin showing ivermectin mortality relative risk RR 0.13, p = 0.04.
11/17
Positive
POSITIVE
PrEP
Carvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007 (Preprint)
cases, ↓99.9%, p<0.0001 Study of the Efficacy and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID-19 in Health Personnel
Prophylaxis study using ivermectin and carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control.
11/14
Positive
POSITIVE
Late
Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)
recov. time, ↓21.1%, p=0.03 Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2
100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment.
11/13
Positive
POSITIVE
PEP
Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v1 (Preprint)
cases, ↓80.0%, p=0.03 Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
RCT for prophylaxis with ivermectin showing a significant reduction in cases with treatment. Relative risk of COVID-19 case RR 0.2, p = 0.03 This paper also reports a treatment study [1].
11/13
Positive
POSITIVE
Late
Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v1 (Preprint)
death, ↓91.7%, p<0.0001 Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
RCT comparing ivermectin + SOC vs. HC Q + SOC, showing a significant reduction in mortality with ivermectin. Mortality relative risk: RR 0.11, p = 0.12 (mild/moderate cases) RR 0.1, p < 0.001 (severe cases) The HC<..
11/13
Review
REVIEW
Review
Kory et al., OSF Preprints, doi:10.31219/osf.io/wx3zn (Review) (Preprint)
Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19
Review recommending the use of ivermectin in both prophylaxis and treatment for COVID-19. Authors report that "the widespread use of this safe, inexpensive, and effective intervention could lead to a drastic reduction in transmission..
11/11
Negative
NEGATIVE
Late
Camprubí et al., PLoS ONE, 15:11, doi:10.1371/journal.pone.0242184 (Peer Reviewed)
ICU, ↓33.3%, p=1.00 Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Tiny 26 patients retrospective study of ivermectin 200 μg/kg, median 12 days after symptoms, not showing significant differences. Authors suggest the dose is too low and recommend evaluation of higher doses. All patients received HC
11/11
Positive
POSITIVE
Early
Krolewiecki et al., SSRN (Preprint)
Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial
Viral load RCT finding a concentration dependent antiviral activity of oral high dose ivermectin at a dosing regimen that is well tolerated. There was no significant difference in viral load reduction between groups overall, but a signif..
11/10
Review
REVIEW
Review
Turkia, M., ResearchGate (Review) (Preprint)
FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 — a brief review
Review suggesting ivermectin should be used based on existing data suggesting significant benefits, and that waiting for additional data may result in significant harm.
11/4
Positive
POSITIVE
Early
Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883 (Preprint)
death, ↓78.3%, p=0.50 Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxych loroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Comparison of HC Q, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated ..
11/3
Positive
POSITIVE
Early, Late
Morgenstern et al., medRxiv, doi:10.1101/2020.10.29.20222505 (Preprint)
The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020
Retrospective 3,099 patients, all receiving ivermectin. Of 2,706 outpatients, there was only 18 hospitalizations, 2 ICU admissions, and 1 death. Of 300 hospitalized patients with moderate cases, 3 died. Of 111 ICU patients, 34 died.
11/3
Positive
POSITIVE
PrEP
Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint)
cases, ↓49.7%, p<0.0001 Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Retrospective prophylaxis study for HC Q, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin. HC
11/2
Animal
ANIMAL
Animal
Arévalo et al., bioRxiv, doi:10.1101/2020.11.02.363242 (Preprint)
Ivermectin reduces coronavirus infection in vivo: a mouse experimental model
Mouse study showing ivermectin reducing MHV viral load and disease. MHV is a type 2 family RNA coronavirus similar to SARS-CoV2.
10/26
Positive
POSITIVE
Late
Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint)
death, ↓66.7%, p=0.27 Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
RCT 70 ivermectin-doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment. The earlier ivermectin+doxycycline was administered, the higher rate of successful therapy.
10/13
Positive
POSITIVE
Late
Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009 (Peer Reviewed)
death, ↓46.0%, p=0.04 Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 [0.22-0.99], p=0.045.
10/9
Positive
POSITIVE
Late
Mahmud et al., Clinical Trial Results, NCT04523831 (Preprint)
death, ↓85.8%, p=0.12 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 180 control patients. Treatment delay is n..
10/8
Theory
THEORY
Theory
Francés-Monerris et al., ChemRxiv, doi:10.26434/chemrxiv.12782258.v1 (Preprint) (Theory)
Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent
In silico study showing that ivermectin is capable of interfering in different key steps of the SARS-CoV-2 replication cycle.
9/30
Negative
NEGATIVE
Late
Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378 (Peer Reviewed)
no recov., ↓10.0%, p=0.50 Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in recovery at day 7.
9/24
Positive
POSITIVE
Late
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
death, ↓87.0%, p<0.05 Ivermectin treatment may improve the prognosis of patients with COVID-19
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance. Some potential issues can be found in [1].
9/22
In Vitro
IN VITRO
N/A
Li et al., J. Cellular Physiology, doi:10.1002/jcp.30055 (Peer Reviewed)
Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
In Vitro study showing Ivermectin is a safe wide-spectrum antiviral against SARS-CoV-2, human papillomavirus (HPV), Epstein–Barr virus (EBV), and HIV. Authors note that the combination of ivermectin and other drugs might result in more f..
9/15
Positive
POSITIVE
Early
Carvallo et al., medRxiv, doi:10.1101/2020.09.10.20191619 (Preprint)
death, ↓87.9%, p=0.05 Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin. There was one death from 167 patients for 0.59% mortality, compared to an estimated overall mortality rate in Argentina of 2.1%. For moderate to severe cases needi..
9/15
Review
REVIEW
Review
Jans et al., Cells 2020, 9:9, 2100, doi:10.3390/cells9092100 (Review) (Letter)
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. Cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, V..
9/3
Inconc.
INCONC.
Late
Podder et al., IMC J. Med. Science, 14:2, July 2020 (Peer Reviewed)
recov. time, ↓16.1%, p=0.34 Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study
Small RCT with 32 ivermectin patients and 30 control patients. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days vs. 6.33 ± 4.23 days in the control arm, p > 0.05. Negative PCR results were not signific..
8/28
Positive
POSITIVE
PEP
Shouman et al., NCT04422561 (Preprint)
cases, ↓91.3%, p=0.001 Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19
PEP trial for asymptomatic close contacts of COVID-19 patients, 203 ivermectin patients and 101 control patients. 7.4% of contacts developed COVID-19 in the ivermectin group vs. 58.4% in the control group, adjusted odds ratio OR 0.087, p ..
8/15
Positive
POSITIVE
Early
Espitia-Hernandez et al., Biomedical Research, 31:5 (Peer Reviewed)
viral+, ↓97.2%, p<0.0001 Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients. All treated patients were PCR- at day 10 while all control patients remained PCR+. The mean duration of symptoms was 3 days in the treatm..
8/14
Positive
POSITIVE
Late
Bhattacharya et al., medRxiv, doi:10.1101/2020.08.12.20170282 (Peer Reviewed)
Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a tertiary care Centre in India- a retrospective case series
Retrospective 148 hospitalized patients showing triple therapy with ivermectin + atorvastatin + N-acetylcysteine resulted in a 1.35% case fatality rate which was well below the national average.
7/31
Theory
THEORY
Theory
Chang et al., ResearchGate (Preprint) (Theory)
COVID-19: Post-exposure prophylaxis with ivermectin in contacts. At Homes, Places of Work, Nursing Homes, Prisons, and Others
Proposed PEP protocol based on ivermectin.
7/31
Inconc.
INCONC.
Late
Alam et al., Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 (Peer Reviewed)
A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline
Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported.
7/31
Positive
POSITIVE
Late
Rahman et al., J. Bangladesh Coll. Phys. Surg. 38, 5-9, doi:10.3329/jbcps.v38i0 (Peer Reviewed)
Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxych loroquine with Azithromycin in COVID-19 Patients
Comparison of 200 patients treated with ivermectin + doxycycline and 200 treated with HC Q + AZ. The HC Q + AZ group had more severe cases at baseline. Viral clearance was faster with ivermectin..
7/14
Inconc.
INCONC.
Early
Chowdhury et al., Research Square, doi:10.21203/rs.3.rs-38896/v1 (Preprint)
A Randomized Trial of Ivermectin-Doxycycline and Hydroxych loroquine-Azithromycin therapy on COVID19 patients
Small 116 patient RCT comparing Ivermectin-Doxycycline and HC Q+AZ, not showing a significant difference in time to PCR negative or symptom resolution. Time to symptomatic recovery was 5.93 days for Ivermectin-Doxycy..
7/8
Positive
POSITIVE
Late
Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint)
death, ↓71.0%, p=1.00 Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin showing a significantly lower mean hospital stay with ivermectin: 7.62 vs. 13.22 days, p=0.00005. 0 of 16 ivermectin patients died vs. 2 of 71 cont..
6/30
In Vitro
IN VITRO
N/A
Caly et al., Antiviral Research, doi:10.1016/j.antiviral.2020.104787 (Peer Reviewed)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
In Vitro study showing that ivermectin is an inhibitor of SARS-CoV-2, with a single addition to Vero-hSLAM cells 2h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48h.
6/19
Theory
THEORY
Theory
Lehrer et al., In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134 (Theory)
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
In silico analysis showing ivermectin docking which may interfere with the attachment of the spike to the human cell membrane.
6/12
Review
REVIEW
Review
Heiday et al., The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z (Review) (Peer Reviewed)
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Review of the antimicrobial, antiviral, and anti-cancer properties of ivermectin. Antiviral effects have been reported for Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki For..
5/2
Positive
POSITIVE
Early
Chang, G., Research Gate, doi:10.13140/RG.2.2.34689.48482/7 (Preprint)
Peru observational case study of 7 patients treated with ivermectin, showing improvement and resolution of fever within 48 hours, and 100% recovery.


Please send us corrections, updates, comments.
Submit